BioNTech (NASDAQ:BNTX) Shares Down 6.5% – What’s Next?

BioNTech SE Sponsored ADR (NASDAQ:BNTX) shares were down 6.5% during mid-day trading on Monday . The company traded as low as $103.80 and last traded at $105.17. Approximately 576,851 shares traded hands during mid-day trading, a decline of 38% from the average daily volume of 928,656 shares. The stock had previously closed at $112.46.

Analyst Upgrades and Downgrades

BNTX has been the topic of several analyst reports. Wells Fargo & Company set a $150.00 target price on shares of BioNTech and gave the company an “overweight” rating in a report on Tuesday, August 5th. The Goldman Sachs Group started coverage on BioNTech in a research report on Thursday, May 29th. They issued a “neutral” rating and a $110.00 target price on the stock. JPMorgan Chase & Co. decreased their target price on BioNTech from $120.00 to $116.00 and set a “neutral” rating for the company in a research note on Thursday, May 22nd. Bank of America raised their target price on BioNTech from $126.00 to $134.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Finally, Leerink Partners set a $112.00 target price on BioNTech in a research note on Monday, June 2nd. Thirteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $135.80.

BioNTech Stock Performance

The business’s 50 day moving average is $109.49 and its two-hundred day moving average is $104.33. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. The company has a market cap of $24.74 billion, a PE ratio of -64.44 and a beta of 1.39.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The business had revenue of $306.46 million during the quarter, compared to analysts’ expectations of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.BioNTech’s revenue for the quarter was up 102.6% on a year-over-year basis. During the same period in the previous year, the company posted ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Banque Cantonale Vaudoise acquired a new position in shares of BioNTech during the first quarter worth $36,000. LRI Investments LLC lifted its position in shares of BioNTech by 234.6% in the second quarter. LRI Investments LLC now owns 445 shares of the company’s stock worth $47,000 after purchasing an additional 312 shares in the last quarter. Tower Research Capital LLC TRC raised its position in BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after acquiring an additional 305 shares in the last quarter. Hantz Financial Services Inc. raised its position in shares of BioNTech by 472.0% in the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock valued at $61,000 after purchasing an additional 472 shares during the period. Finally, Banque Transatlantique SA bought a new position in BioNTech during the first quarter worth $80,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.